CNNC Fuzhi Officially Established, CNNC Isotope Holds 90% Stake to Integrate the Full Nuclear Medicine Industry Chain

On August 6, 2026, CNNC Fuzhi (Beijing) Technology Co., Ltd. (hereinafter referred to as "CNNC Fuzhi") was officially established. The company was jointly funded by CNNC Isotope Co., Ltd. (hereinafter referred to as "CNNC Isotope") and CNNC (Zhejiang) Innovation Co., Ltd. (hereinafter referred to as "CNNC Zhejiang Innovation"), with CNNC Isotope holding 90% of the shares and CNNC Zhejiang Innovation holding 10%.

CNNC Fuzhi will take over the business of CNNC Isotope's Nuclear Medicine Development Center, focusing on deep cultivation in the smart nuclear medicine sector. With the smart nuclear medicine IoT system as its core carrier, the company aims to integrate the entire "nuclear medicine" industry chain, build a synergistic development model of "smart nuclear medicine system + nuclear drugs + equipment + services," and upgrade its business from "single product supply" to "full value chain integrated services," facilitating the standardization and intelligent transformation of the nuclear medicine industry, improving the industrial ecosystem, and cultivating new profit growth points.

CNNC Isotope is a subsidiary of China National Nuclear Corporation (CNNC) and a national champion and leading enterprise in China's nuclear technology application sector. It has established a "6+N" business layout with six core businesses—radionuclides, radiopharmaceuticals, nuclear medicine equipment, integrated nuclear medicine solutions, radiation sources and applications, and irradiation applications—complemented by import/export of core products and other strategic emerging industries. After more than 40 years of development, CNNC Isotope has formed a complete nuclear technology application industry chain covering R&D, production, sales, and services, maintaining a leading position in domestic production capacity and service scale.

CNNC Zhejiang Innovation was jointly established by CNNC (Beijing) Innovation Co., Ltd. and Hangzhou Science and Technology Innovation Group Co., Ltd. Leveraging CNNC's scientific research expertise and industrial heritage, combined with Hangzhou Sci-Tech Innovation's capital and industrial cluster advantages, the company adheres to the positioning of "investing early, investing small, and investing in hard tech," focusing on key technology breakthroughs and industrial chain upgrades in the nuclear industry, and promoting the commercialization of scientific research achievements and regional industrial synergy.

The collaboration between CNNC Isotope and CNNC Zhejiang Innovation will form a complementary pattern of "industrial foundation + capital empowerment," providing all-round support for CNNC Fuzhi's business expansion and capitalization process, jointly promoting the high-quality development of the smart nuclear medicine industry and injecting new momentum into the digital transformation of the nuclear medicine industry.